Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Danielm89, 17 May 2024 11:33
Last post: 01234, 19 Jun 2024 17:40
Another huge trade this time a sell . Crazy
Verici is a very tasty little morsel for Thermo ,only a matter of time.
I’m trying to remain calm about that huge £150 grand buy but it’s tricky ! What a statement of intent from somebody . I would imagine it would garner some reaction from onlookers. Everything crossed this is starting to show its potential . So undervalued right now
Big big biggy!!
Big buy went through very interesting!
Started: scoredagainsteps, 26 Apr 2024 15:24
Last post: 01234, 16 May 2024 15:45
Could well arrive earlier if good news. Just sayin
Results due early June so wait for that!
Would be good to see this close above 9.00+ today
I don’t know why but I got a good feelin in ma bones
Lol they’ve cranked up the rude setting on the bot dials. Funny old game this aim
Started: janet2007, 15 May 2024 15:15
Last post: janet2007, 15 May 2024 15:15
In the top 50 risers ...yes smkr buys coming in strong rerating coming
Started: janet2007, 15 May 2024 15:13
Last post: janet2007, 15 May 2024 15:13
See 10.00+ coming very soon
Started: scoredagainsteps, 1 May 2024 17:03
Last post: 01234, 15 May 2024 13:36
Maybe a positive update sooner than we think
Wow we are blue. this should never have been under 9. silly sellers robbed themselves in medium term imo
news will come, and cash runway until 2026.
remember where they’re at:
https://www.biopharma-reporter.com/Article/2023/11/16/Verici-Dx-receives-boost-with-Thermo-Fisher-licensing-deal
Well someone is 300k shares heavier this morning !
No progress report and we are in mid May beggars belief to be frank !
dear verici management.
please dont treat shareholders as "space ***** es "ie jeremy
clarkson
ie mushrooms .we invested in your cash call wholeheartdly and deserve the decency of being kept updated on progress.
Started: scoredagainsteps, 6 Apr 2024 09:36
Last post: 01234, 26 Apr 2024 14:37
Agreed . But more volume today
Placing done at 9p. At this price - it's way too cheap with Thermo Fisher deal.
Flat is an understatement. Large trades being slowly worked through over the last few weeks. Maybe we’ll hear something once that’s done. Whatever that is!
Oh what was that ? ANOTHER £100 k trade nestled in between the 5 odd tiny buys and sells this month??
Nothing to see here honest . What a crazy game aim is
Another casual £100k trade slipped in there without an eyelid batted.
Started: BeastlyD, 25 Apr 2024 10:37
Last post: BeastlyD, 25 Apr 2024 10:37
Anyone aware of any future updates we're expecting? Feel this has gone a bit flat, needs a trading update or something.
Started: scoredagainsteps, 5 Mar 2024 09:58
Last post: smkr, 5 Apr 2024 20:52
Yeah we could do with an update now. Seems quite odd selling into this week, and I can only assume it’s some taking bits off the table at end of tax year. As Silverblade just said below, it’s fully funded for a decent amount of time for partners / commercial opportunities to develop, with high institutional support, So let’s see..
I was thinking just the same donmac.......for a company which has c.£9m in the bank to fund it through to 2026 its not exactly performing the way we would like with a total market cap of just over £20m. Tutiva appears to be the victim of a slower take up than previously assumed, although the thermo deal for Clarava bodes well for the company's suite of products. Like most new and innovative products, the clinical market needs time to assess and evaluate the tests before moving forward with order commitments, despite the clinical, financial and regulatory evidence before it. Much like sister company Renx. I'm still buying at this price. SB
Please miss Barrington an operational update would be very nice .Thank you.
Strange move today. They would take a ton of shares in one go when they dropped the bid. Lets see over coming days
Wow wow
There will definitely be eyes, considering VRCI was a spin out from Renx
On target for take over ,but one would prefer a higher sp for a start.
In the usa they have a tendency to buy out little uk companies, as they have ben undervalued for some time.
Just having a look I would hope Veri are in a stronger position than them . Not much bargaining power given they’re running on fumes it seems
That’s exactly what I mean with this being a potential takeout target .. I agree Donmac
What is it with these pharma stock boards theirs is quieter than here!
Interesting. I wonder what the offer is
Renalytix taken out this morning?
Takeover on the cards here shortly as vrci flavour of the month.
Hey a fellow Brony! Nothing to be ashamed of my friend . Atb
Then you can put it with the rest of your my little pony collection.
Unicorn!
Started: 01234, 31 Jan 2024 07:15
Last post: smkr, 19 Feb 2024 21:47
Wow what was that trade reported after hours
Less goooo
Seems quite a few that didn’t get their full allocation are buying .. only got around 3rd of what I applied for with Ajbell .,
15mill market cap laughable when you consider the IP this little gem is sitting on.
Think this should gain traction with fundraise success out the way.Thermo Fishers shadow lurking in the background wont want it to get away .Bid could happen short term methinks!
Started: 01234, 24 Jan 2024 19:31
Last post: 01234, 29 Jan 2024 07:43
Nice big buy from Thursday popped up
Funded to 2026 and won’t be last of the commercial deals. If Thermo Fisher was a taster then things look good. I’ve applied for a few more with the retail offer. Hopefully I get them all, looks like the main placing went fast!
..think they'll be pushing on many open doors in terms of kidney transplant centres, once they have the first clinicians using Clarava in a real-world live environment the word will spread, trusted sources couching for the product will only help leverage any sales efforts.
The high share price was back in the go go days of non-existent interest rates so outlier imho. That said if they execute and the TMO partnership develops then this is significantly undervalued.
Been watching this for years off the back of RENX and eventually started a small position at end of the year. Major caveat I had was cash position and that seems to have been addressed at least for the next 12/18 months depending on cash burn.
Just hope the US election doesn't add too much grid lock to roll out of products.
Amazing products. Highest price paid 81p, lowest 6.5p. Average = 21p.
Is it worth less than 81p now, with the Thermo fisher deal and all the approvals? Does anyone have a "back of the envelope "valuation?? Looking forward to taking a chunk in the placing. GLA
Started: Deadgrateful, 24 Jan 2024 08:42
Last post: Feeks, 24 Jan 2024 11:37
Nicely benefitting the insurance company's premiums!!
Book build closed nice and quick.
Got it Cliveas, ouch… I’m in around 20p from the IPO and a few more since, I did manage to add a few arlund the 7p level, not that it improved my average much!
Onwards ho then!
Well not great for me.
Last one 35p.
But it will fund the success of this company and eventual takeover.
GL.
That was a fund dumping 350 k shares this morn. Price on the way back up.
Started: OAPK20, 24 Jan 2024 07:18
Last post: Deadgrateful, 24 Jan 2024 09:05
Yes, hence the long reaching raise. Better for them to lower expectations and plan for it, leaving plenty of room for upside (imo). The dilution is a necessary of the raise and not too bad when you consider the new cash runaway. I think it’s a well run company with huge prospects, and a little gem amongst so many other risky pharma stocks (well, this and ROQ have my main attention).
It also diminishes the risk of Thermo coming in with a low ball offer!
Beast - it’s 36% dilution (not including the separate conditional retail offer ) and not to mention ;
“ The Company recognises the risks associated with the launch of a new test (including the time to obtain the initial Local Coverage Determination) and taking into account the potential timing effects of this for the build-up of Tutivia(TM) sales in 2024, is reducing its expectations for Tutivia(TM) revenue for 2024. The effect of this reduction is expected to be at least partially offset by revenue from other sources including research collaborations. “
It’s a cash raise which is hardly ever good news for investors but it’s been negotiated at a good price . Still think it’s good a lot of potential
Buy some more and reduce your average only upside from here!
Started: EarlofAim, 8 Jan 2024 12:23
Last post: smkr, 23 Jan 2024 11:56
Can you imagine the scramble to get in when the Thermo Fisher payment arrives? These last raised cash at 35p and that was before they signed commercial deals. There will be plenty support for this in size and not at these depressed prices
Lotta kidneys, lotta monies. Very quiet here though . Watchin and waitin
Approx 400-500 (including living donor transplants) per week. So with around 100 per week using both Tutivia(TM) (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava(TM) (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection
Then $265000 per week or $13,780,000 per annum. ?
Is that about right?
Half of these posters must be chat gpt . Messages like that are pure oxymoronic nonsense .
Yeah i will pay 50% more for a company needing a loan.
Talk sense man
Started: Hawker, 8 Jan 2024 12:15
Last post: Hawker, 8 Jan 2024 12:15
..drivel and pump and dumpers aside, Verici looks set to pick up testing momentum heading into the second half, as sales via Thermo Fischer are scheduled to get underway during Q2. I would expect a fair bit of news flow around the start of that process and assuming sales go well then perhaps the shares can move to recover their IPO price of 20p and build further from there.
Regarding potential testing volumes, there were reportedly ~25k kidney transplants in the US in 2022 and the company usually references an annual number of 20k for the US, conducted across the 200 or so kidney transplant centres.
"In 2022, a record 25,498 kidney transplants were performed in the US, according to the United Network for Organ Sharing (UNOS)."
Assuming Thermo Fischer has full coverage of the kidney transplant centres and a steady adoption of the Verici testing suite, would it be cautious to estimate 1-3% in their first year, so 250-750 transplants? How many tests per transplant, 1-3? So an initial guide range of 250-2250 tests at $2,650 per test? This implies a gross revenue range of $663k to £$6m at full rate.
Thinking further ahead let's assume they achieve a market share of say 15% in Year 2 and maybe a bullish 30% in Year 3... Again, assuming a testing rate per transplant of 1-3 then this implies a revenue range of $10m-$30m for Year 2 and $20m-$60m for Year 3.
I have no clue if any of this is possible, or realistic, but what I like about it is the low end numbers easily underpin the current valuation and therefore any positive surprise to this suggests plenty of upside and who knows what level of activity and testing adoption rates lead to Thermo Fischer progressing their relationship with Verici to a full acquisition/take over?
Net net, 10-11p or market cap of £18m (no debt and £5m+ cash) looks like a good opportunity to me!
Nb, I have been a holder since they IPO'd back in 2020, sold a few into the spike around 60-80p and have been steadily buying those back and more over the past year.
GLA and DYOR!
Started: EarlofAim, 8 Jan 2024 09:02
Last post: BeastlyD, 8 Jan 2024 11:47
Yawn... I'm falling asleep listening to your drivel.
Today's rns is a fantastic opportunity to buy vrci. and the fact sp not moved gives me to load up at these bargain SP
Thermo Fisher are not stupid..... they have world class researchers at their disposable who decided to partner with VRCI.
market makers are asleep in this
Based on the muppet numbers....
PE of 10 requires £1.9m of annual profit to sustain the current share price. That would be less than 3p a test for capturing the whole market of 69.3m patients. Plenty of upside then
69m medicare clients ya muppettito are they all needing a kidney transplant!!!!
Started: petroinvestor, 8 Jan 2024 09:10
Last post: 01234, 8 Jan 2024 09:22
Nah . I think beware of people trying to give advice about other posters .
Oh dear EarlofAim, how many stocks you and Ria20 P&D and the newbies left holding the baby?
Beware of people who give you stock tips with random price targets. They are likely pump-and-dumpers who are trying to offload their shares at a higher price. Newbies often fall for this scam and end up losing money.
EarlofAim Twitter accounts:
Equity-Trader - https://twitter.com/EquityTrader888
Investology - https://twitter.com/Profitprofit1
Check for yourself how many pump-and-dump posts he posts every day and back it up with his LSE posts to scam investors.
Started: EarlofAim, 8 Jan 2024 08:51
Last post: EarlofAim, 8 Jan 2024 08:54
Wow!!
$2650 per test and X 63.9m is $169 billion market to be fulfilled by the likes of VRCI
this is huge potential to become mid tier company
Medicare National Payment Rate for Tutivia? and Clarava? Effective as of January 1, 2024
CMS finalises gapfill median rate at $2,650 per test
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule ("CLFS") payment rate of $2,650 established through the "gapfill" process for both Tutivia? (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava? (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.
Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients.
Great news. Great to see the payment rates confirmed. The consistent positive updates are building a solid platform. VRCI has to be on the radar for a big player to come in
Started: happytrades, 8 Dec 2023 10:47
Last post: 01234, 8 Jan 2024 07:08
Two great rns what a Monday morning . Great work team Verici dx .
Remember Clarava and Tutivia are now both in the market as real products and with Thermos sales team driving sales 2024 is looking amazing.
Pharma is coming back into favour.Verici has best in class products and iam sure Thermo will take it out this year ,climb aboard now.
That's the kind of thing you type as you press sell for 20k lol
This is getting ready to pop ,great value here totally undervalued .3great products 1st in class and one of the worlds largest pharmas backing to boot just a matter of patience.
Great news!
Opens the doorway for deeper relations with Thermo Fisher and also other JV/collaborations!
GL.
Started: 01234, 23 Nov 2023 12:06
Last post: 01234, 29 Nov 2023 07:14
Great rns people should be very interested in this share
A distinct lack of interest it seems. For now
This ain’t going to well
Started: Giovs, 20 Nov 2023 08:29
Last post: Parkers67, 22 Nov 2023 21:57
I was in work so was watching but never got all the detail, however I didn't hear anything that we haven't heard before. More of a confirmation the company is on the right path although did mention possibility of more deals with Thermo in time. I don't expect the share price to go up massively on the back of it.
Would love to be wrong of course.
I can't really remember much it was just her tone I picked up on. It's not going to have explosive growth but its going to be big was the nub of it.
Spill the beans then 🤔
Mmm. That was a very confident woman.
It would make sense to have an investor call alongside confirmations of the median rate for both Tutivia and Clarava. And the commercial use of the latter ahead of the call.
I missed the 9am deadline, but hopefully if no RNS tomorrow they will confirm these are still objectives for 2023.